#NonHodgkinLymphoma
LightNews LightNews
edwardsdna.bsky.social
Incredible Results from 20 Years of Cancer Research Boost National Survival Rates to 7 in 10: In what is being called a major milestone in American cancer research and treatment, 5-year survival… @goodnewsnetwork.org #CancerResearch #CancerSurvival #HealthMilestone #Leukemia #NonHodgkinLymphoma
Incredible Results from 20 Years of Cancer Research Boost National Survival Rates to 7 in 10
In what is being called a major milestone in American cancer research and treatment, 5-year survival rates averaged across all cancers have never been higher, with 7-in-10 cancer patients living past 5 years post-diagnosis. This average was pumped up by large survival rate increases in leukemia (20%), non-Hodgkin lymphoma (18%), and ovarian cancer (9%) over […] The post Incredible Results from 20 Years of Cancer Research Boost National Survival Rates to 7 in 10 appeared first on Good News Network.
dlvr.it
January 22, 2026 at 8:10 PM
nnhla-natcan.bsky.social
🎉 New Release Alert!
The latest update to the National Non-Hodgkin Lymphoma Audit (NNHLA) data dashboard is now live!
🔗 Access the dashboard here: rcs-ceu.shinyapps.io/NNHLA/

@natcan-news.bsky.social @hqip.bsky.social
@bsochaem.bsky.social
#BloodCancer #nonHodgkinlymphoma #Audit #NHSE #Hospitals
rcs-ceu.shinyapps.io
January 8, 2026 at 11:01 AM
bionewscentral.com
Measuring a patient’s absolute #LymphocyteCount can help predict their response to #CARTcelltherapy for #NonHodgkinLymphoma, providing a practical tool to guide #TreatmentDecisions.
#TherapyResponse #ClinicalOutcomes
A routine blood test could help predict who benefits most from CAR T-cell therapy – BioNews Central
Measuring a patient’s absolute lymphocyte count can help predict their response to CAR T-cell therapy for non-Hodgkin lymphoma, providing a practical tool to guide treatment decisions. ...
sbee.link
December 9, 2025 at 4:22 PM
pharmaphorum.bsky.social
NICE backs #NHS use of Roche's Columvi as a second-line therapy for a form of #NonHodgkinLymphoma affecting thousands of people in the UK each year.
pharmaphorum.com/news/nice-ba...
#LymphomaResearch #BloodCancer #OncologyInnovation #LifeSciences #PharmaNews
NICE backs Roche's non-Hodgkin lymphoma drug Columvi
NICE backs NHS use of Roche's Columvi as a second-line therapy for a form of non-Hodgkin lymphoma affecting thousands of people in the UK each year
pharmaphorum.com
November 13, 2025 at 1:37 PM
vjhemonc.bsky.social
Want to gain insight into the use of bispecific antibodies & other immunotherapies in early lines of treatment for #NonHodgkinLymphoma?🩸

Check out our discussion from #iwNHL25, with leading experts @DocHutchings, @elizabeth_budde, Lorenzo Falchi, & Sameh Gaballa:

🎥 buff.ly/CPiM5kC

#LYMsm #HemOnc
October 31, 2025 at 9:29 AM
vjhemonc.bsky.social
Gray zone lymphoma is a rare subtype of #NonHodgkinLymphoma. 🩸

Learn more about this entity from Kieron Dunleavy:

👉 buff.ly/VPFTEid 👈

#LYMsm #Lymphoma #HemOnc #SOHO2025 #BloodSky #HemeSky #MedSky
October 10, 2025 at 9:02 AM
nnhla-natcan.bsky.social
🎉 New Release Alert!
The National Non-Hodgkin Lymphoma Audit (NNHLA) October quarterly data dashboard is now live! buff.ly/5sixc0j

@natcan-news.bsky.social @hqip.bsky.social
@bsochaem.bsky.social

#Cancer #BloodCancer #NHL #nonHodgkinlymphoma #ClinicalAudit #Audit #Data #NHSE #Hospitals #Trusts
National Non-Hodgkin Lymphoma Audit (NNHLA) - National Cancer Audit Collaborating Centre
We use some essential cookies to make this website work.
bit.ly
October 9, 2025 at 9:30 AM
hqip.bsky.social
Don’t miss @nnhla-natcan.bsky.social @natcan-news.bsky.social @hqip.bsky.social recent report on care received by people diagnosed with non-Hodgkin lymphoma.

Read the full report here 👉: hqip.org.uk/resource/635...

#NonHodgkinLymphoma #BloodCancer
October 2, 2025 at 3:28 PM
vjhemonc.bsky.social
🎥 Ranjit Nair of @mdanderson.bsky.social shares the promising results of a Phase I study evaluating surovatamig (AZD0486), a CD19-targeting bispecific T-cell engager, in patients with R/R #NonHodgkinLymphoma:

🎥 👉 buff.ly/k5zLkkg

#SOHO2025 #LYMsm #Lymphoma #CTSM @societyofhemonc.bsky.social
September 29, 2025 at 4:05 PM
nnhla-natcan.bsky.social
👀📰Please take a moment to review our latest newsletter from the National Non-Hodgkin Lymphoma Audit (NNHLA) project team.

Check it out here: bit.ly/3IAj4UN

#Cancer #nonHodgkinlymphoma #NHL #Bloodcancer #BCAM #ClinicalAudit #Audit #Data #NHSE #Hospitals

@hqip.bsky.social
@natcan-news.bsky.social
NNHLA Newsletter, September 2025 - National Cancer Audit Collaborating Centre
bit.ly
September 23, 2025 at 3:05 PM
4040rec.bsky.social
#NHSScotland #ScottishMedicinesConsortium #Haematology #BeOneMedicinesUK #BeOne #SMC #SMCrecommendation #zanubrutinib #BRUKINSA #relapsedmantlecelllymphoma #MCL #MCLpatients #refractorymantlecelllymphoma #nonHodgkinlymphoma #LymphomaAction #BeatsonWestofScotlandCancerCentre
zurl.co/lk0uJ
Scotland approves zanubrutinib for relapsed mantle cell lymphoma - PharmaTimes
New treatment option now available across all UK nations
pharmatimes.com
September 1, 2025 at 8:40 AM
vjhemonc.bsky.social
BOOM-BOOM radiation is a form of very low-dose radiation administered over two fractions.

Watch as Christopher D’Angelo of @unmc.bsky.social discusses the feasibility & safety of its use prior to liso-cel for aggressive B-cell #NonHodgkinLymphoma:

👉 buff.ly/42xhT8E

#LYMsm #Lymphoma #RadOnc
August 17, 2025 at 2:02 PM
vjhemonc.bsky.social
Following #18ICML, we had the pleasure of catching up with Nilanjan Ghosh to hear his highlights in #NonHodgkinLymphoma from this year’s meeting.🩸

Click here for the comprehensive overview:
👉 buff.ly/RQDPS8G

#DLBCL #MantleCellLymphoma #FollicularLymphoma #LYMsm #CTSM #Lymphoma #ImmunoOnc
August 5, 2025 at 8:01 AM
vjhemonc.bsky.social
In an interview from #18ICML, Nikhil Mankuzhy of @mskcancercenter.bsky.social provides insight into the efficacy of response-adapted very low-dose radiotherapy at a dose of 4 Gy for indolent #NonHodgkinLymphoma:

🎥 buff.ly/bLGk41w

#LYMsm #Lymphoma #RadOnc #HemOnc #BloodSky #HemeSky #MedSky
August 3, 2025 at 3:01 PM
todayinnerdhistory.bsky.social
Remembering Jacqueline Kennedy Onassis, born July 28, 1929 and passed away May 19, 1994.

Full Post
www.facebook.com/photo/?fbid=...

#TodayInNerdHistory #July28 #JacquelineKennedyOnassis #JacquelineKennedy #JackieO #NonHodgkinlymphoma #FirstLady #UnitedStatesOfAmerica #USA #America #Birthday
July 28, 2025 at 1:15 AM
nnhla-natcan.bsky.social
🚀 Exciting news! The National Non-Hodgkin Lymphoma Cancer Audit (NNHLA) July quarterly data dashboard is now live! 🎉

👉 www.natcan.org.uk/reports/nnhl...

@natcan-news.bsky.social @hqip.bsky.social

#BloodCancer #NonHodgkinLymphoma #ClinicalAudit #Audit #Data #NHSE #Hospitals
NNHLA Quarterly Data Dashboard - National Cancer Audit Collaborating Centre
The purpose of the National non-Hodgkin lymphoma Audit (NNHLA) is to evaluate the patterns of care and outcomes for people diagnosed with non-Hodgkin lymphoma (NHL) in England and Wales, and to…
www.natcan.org.uk
July 10, 2025 at 11:00 AM
hematologyadvisor.bsky.social
For patients in Malawi with advanced pediatric MB-NHL, treatment with HD-MTX appeared feasible, in the absence of routine MTX monitoring, in a recent study. Reported in @ascocancer.bsky.social JCO Global Oncology.

bit.ly/3HAnAC2

#lymsm #NonHodgkinLymphoma
HD-MTX Treatment Feasible in Advanced Pediatric MB-NHL in Malawi
Researchers determined it is feasible to administer treatment with HD-MTX for pediatric patients with advanced MB-NHL in Malawi.
bit.ly
June 11, 2025 at 4:12 PM
nnhla-natcan.bsky.social
Celebrating Clinical Audit Awareness Week (#CAAW25) from June 2 to 6, 2025! 🎉 This is a fantastic opportunity to highlight the benefits and impact of clinical audits and quality improvement initiatives in healthcare. 🏥

#BloodCancer #NonHodgkinLymphoma #ClinicalAudit #Audit #Data #NHSE #Hospitals
hqip.bsky.social Healthcare Quality Improvement Partnership (HQIP) @hqip.bsky.social · Jun 2
🎉 Clinical Audit Awareness Week 2025 #CAAW25 is here!

In partnership with National Quality Improvement (Incl. Clinical Audit) Network (N-QI-CAN), join us for a week-long celebration of the critical role of clinical audit in healthcare improvement.
June 2, 2025 at 2:32 PM
nnhla-natcan.bsky.social
#BloodCancer #NonHodgkinLymphoma #ClinicalAudit #Audit #Data #NHSE #Hospitals #StateoftheNationalReport
May 20, 2025 at 9:18 AM
onclive.bsky.social
AlloNK Plus Rituximab Induces Durable Responses in R/R B-Cell NHL
#nonhodgkinlymphoma #lymsm
www.onclive.com/view/allonk-...
AlloNK Plus Rituximab Induces Durable Responses in R/R B-Cell NHL
Longer-term phase 1/2 data with AB-101 plus rituximab showed high, durable responses in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
www.onclive.com
May 14, 2025 at 6:09 PM
thrivingwithcancer.bsky.social
I thought it was just fatigue.
Then night sweats.
It turned out to be stage 3 lymphoma.
In my new video, I’m sharing the symptoms I ignored — in case it helps someone else.
🎥 Watch now: www.youtube.com/watch?v=5x0V...
💜 #lymphomasymptoms #bloodcancer #nonhodgkinlymphoma
Symptoms I Ignored Before My Lymphoma Diagnosis
YouTube video by Thriving with Cancer
www.youtube.com
May 2, 2025 at 8:13 PM
nnhla-natcan.bsky.social
Exciting news! 🎉 Members of the National Non-Hodgkin Lymphoma Audit (NNHLA) project team will attend the British Society for Haematology Annual Scientific Meeting on 27th and 29th April! 📷

@natcan-news.bsky.social
@bsochaem.bsky.social

#BloodCancer #NonHodgkinLymphoma #NHSE #BSH2025
April 25, 2025 at 12:45 PM
thrivingwithcancer.bsky.social
I’m a lymphoma patient, and I’ve always wondered what made these two types different. So I broke it down in real language — symptoms, treatment, and what I wish I knew at diagnosis.
💜 Watch now: www.youtube.com/watch?v=Gf37...

#Lymphoma #CancerAwareness #NonHodgkinLymphoma #HodgkinLymphoma
Hodgkin’s vs. Non-Hodgkin’s Lymphoma – What’s the Difference?
YouTube video by Thriving with Cancer
www.youtube.com
April 24, 2025 at 8:34 PM
oncodaily.bsky.social
Living Proof: Remission with Purpose - Daniel Flora
@dbfloramd.bsky.social

oncodaily.com/blog/daniel-...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #NonHodgkinLymphoma #LivingProof
Daniel Flora: Living Proof - Remission with Purpose - OncoDaily
Daniel Flora: Living Proof - Remission with Purpose / cancer, Daniel Flora, Non Hodgkin lymphoma, OncoDaily, Oncology, St. Elizabeth Healthcare
oncodaily.com
April 19, 2025 at 9:50 PM
nnhla-natcan.bsky.social
♻️ Please repost to promote awareness of our work
🔔 Follow us for more updates
🖥️ Sign up for news from the NNHLA team, by emailing us at:
[email protected] 📧
🔎Visit the NNHLA website for more information:
www.natcan.org.uk/audits/non-h...

#BloodCancer #NonHodgkinLymphoma #Datadashboards #NHSE
LinkedIn
This link will take you to a page that’s not on LinkedIn
lnkd.in
April 17, 2025 at 4:23 PM